TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05356741: To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER

Sponsor: Vir Biotechnology, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 645 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05356741 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05356741 Rescue Dossier →